Side-by-side · Research reference
ARA 290vsMatrixyl
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED17/59 cited
BAnimal-MechanisticHUMAN-REVIEWED9/39 cited
Matrixyl
Cosmeceutical Pentapeptide · Topical Anti-Aging
Topical · Dermal · Twice Daily
01Mechanism of Action
Parameter
ARA 290
Matrixyl
Primary target
Innate repair receptor (EPO receptor / CD131 heterodimer)
Dermal fibroblastsPaccola 2025
Pathway
EPO/CD131 → JAK2 activation → PI3K/AKT, MAPK signaling → anti-inflammatory, anti-apoptotic cascades
Fibroblast stimulation → Collagen I/III/IV synthesis → Glycosaminoglycan deposition → ECM remodeling
Downstream effect
Tissue protection, nerve fiber regeneration, suppression of inflammatory macrophage activation, altered T-cell differentiation (↑Treg, ↑Th2, ↓Th1)Liu 2014Culver 2017
Enhanced extracellular matrix synthesis, improved dermal density, collagen remodelingPaccola 2025
Origin
11-amino-acid sequence from EPO helix B, engineered to eliminate hematopoietic activity while retaining tissue-protective properties
Synthetic pentapeptide KTTKS derived from pro-collagen I fragment, N-palmitoylated for lipophilicityGomes 2022
Antibody development
Not reported in clinical trials
—
02Dosage Protocols
Parameter
ARA 290
Matrixyl
Standard dose (Phase 2)
4 mg / dayBrines 2015Culver 2017
Sarcoidosis SFN and diabetic neuropathy trials.
—
Frequency
Once daily
Self-administered subcutaneously.
—
Duration
28 days (Phase 2)Culver 2017
Corneal nerve improvements observed by day 28.
8–12 weeks minimum for visible effect
Collagen synthesis requires sustained application.
Evidence basis
Phase 2 RCTsCulver 2017Brines 2015
64-subject sarcoidosis trial, type 2 diabetes trial.
—
Timing
Any time of day
No circadian dependence reported.
—
Formulation concentration
—
0.5–5% in topical vehicle
Common cosmeceutical range; higher concentrations in clinical formulations.
Application frequency
—
Twice daily (AM/PM)
Standard cosmeceutical protocol.
Vehicle
—
Serum, cream, or emulsion base
Lipophilic carriers enhance penetration.
03Metabolic / Fat Loss Evidence
Parameter
ARA 290
Matrixyl
Primary effect
Improved metabolic control (HbA1c, fasting glucose)Brines 2015
Secondary to neuropathy treatment; direct lipolytic effects not established.
—
HbA1c
Significant reduction vs placebo
Observed in type 2 diabetes + neuropathy trial.
—
Fasting glucose
Improved in ARA 290 group
—
Body composition
Not directly quantified
Fat loss not a primary endpoint; metabolic improvements may reflect insulin sensitivity.
—
04Side Effects & Safety
Parameter
ARA 290
Matrixyl
Injection site reaction
Mild, transient
—
Hematopoiesis
None — non-erythropoietic
Distinguishes ARA 290 from native EPO.
—
Cardiovascular
No thrombotic events or hypertension reported
—
Immunogenicity
No antibody formation reported
—
Irritation
—
Mild erythema, pruritus in sensitive skin (rare)
Allergic reaction
—
Contact dermatitis (uncommon)
Systemic absorption
—
Negligible — topical application only
Absolute Contraindications
ARA 290
- ·Hypersensitivity to ARA 290
Matrixyl
- ·Known hypersensitivity to palmitoyl peptides
Relative Contraindications
ARA 290
- ·Active malignancy (theoretical EPO-axis concern; not observed in trials)
Matrixyl
- ·Active dermatitis or open wounds at application site
05Administration Protocol
Parameter
ARA 290
Matrixyl
1. Preparation
Reconstitute lyophilised powder per manufacturer instructions. Use sterile technique.
Wash face with gentle cleanser. Pat dry.
2. Injection site
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites to avoid lipohypertrophy.
Apply 2–3 drops to fingertips. Massage gently into target areas (face, neck, décolletage). Allow 1–2 minutes for absorption.
3. Timing
Once daily, any time of day. Self-administered in Phase 2 trials.Brines 2015
Twice daily — morning and evening. Apply before heavier creams or sunscreen.
4. Dosing
4 mg daily for 28 days (Phase 2 protocol). Duration for chronic use not established.Culver 2017
Store at room temperature, away from direct sunlight. Stable in formulation for 12–24 months.
5. Storage
Lyophilised: store at controlled room temperature. Reconstituted: refrigerate, use within specified timeframe.
—
06Stack Synergy
ARA 290
+ BPC-157
ModerateARA 290 targets the innate repair receptor (EPO/CD131) for nerve regeneration and anti-inflammatory signaling, while BPC-157 promotes angiogenesis and tissue repair through distinct mechanisms (likely involving VEGF, growth hormone receptor pathways). Combined, they may address both neuroinflammation and structural tissue repair in neuropathy or injury models. No direct clinical data; mechanistic overlap in tissue protection.
- ARA 290
- 4 mg SQ · daily
- BPC-157
- 250–500 mcg SQ · daily
- Frequency
- Once daily, same or separate injections
- Primary benefit
- Nerve regeneration, pain reduction, tissue healing
Matrixyl
+ GHK-Cu
Multi-pathwayMatrixyl (Pal-KTTKS) stimulates fibroblast collagen synthesis via pro-collagen I mimicry, while GHK-Cu acts as a copper-binding tripeptide that enhances ECM remodeling through metalloproteinase modulation and wound healing pathways. Combined, they address collagen synthesis (Matrixyl) and matrix remodeling/repair (GHK-Cu) through distinct mechanisms, producing complementary effects on dermal architecture.
- Matrixyl
- 0.5–5% topical serum · AM/PM
- GHK-Cu
- 1–2% topical serum · same application
- Frequency
- Twice daily
- Primary benefit
- Enhanced collagen synthesis + ECM remodeling, improved skin density and elasticity